<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001009</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 060</org_study_id>
    <secondary_id>11034</secondary_id>
    <nct_id>NCT00001009</nct_id>
  </id_info>
  <brief_title>A Study of Dextran Sulfate in HIV-Infected Patients and in Patients With AIDS or AIDS Related Complex (ARC)</brief_title>
  <official_title>A Phase I/II Dose Ranging Trial of Oral Dextran Sulfate (UA001) in HIV Infected Individuals and in Patients With Acquired Immunodeficiency Syndrome (AIDS) or AIDS Related Complex (ARC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To determine the effectiveness and safety of dextran sulfate (DS) as a treatment for patients&#xD;
      with AIDS, AIDS related complex (ARC), or asymptomatic HIV infection with or without&#xD;
      persistent generalized lymphadenopathy (PGL), and to determine antiviral activity at&#xD;
      different doses of DS. Although zidovudine (AZT) has shown promise in prolonging life in&#xD;
      patients with AIDS and severe ARC, it has significant blood toxicities. It would be&#xD;
      beneficial to combine AZT with another antiviral agent that does not have the same toxicity.&#xD;
      DS might be a suitable drug since it has shown antiviral activity against HIV in the&#xD;
      laboratory, and in preliminary studies it has shown little toxicity. Also, the combination of&#xD;
      DS with AZT has been shown to be more effective than either alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although zidovudine (AZT) has shown promise in prolonging life in patients with AIDS and&#xD;
      severe ARC, it has significant blood toxicities. It would be beneficial to combine AZT with&#xD;
      another antiviral agent that does not have the same toxicity. DS might be a suitable drug&#xD;
      since it has shown antiviral activity against HIV in the laboratory, and in preliminary&#xD;
      studies it has shown little toxicity. Also, the combination of DS with AZT has been shown to&#xD;
      be more effective than either alone.&#xD;
&#xD;
      The study will begin with 10 patients with AIDS, 10 with ARC, and 10 with asymptomatic HIV&#xD;
      infection taking DS by mouth 3 times a day for 24 weeks. If the initial dose of DS is&#xD;
      tolerated without significant side effects, the next group of patients will receive a higher&#xD;
      dose. A third group of patients will be given either a higher or lower dose depending on the&#xD;
      results of the earlier groups. Patients will be evaluated every other week for 12 weeks, then&#xD;
      monthly for the remaining 16 weeks. Patients will have the option of continuing DS until the&#xD;
      entire study is completed if the drug is well tolerated. Inhaled pentamidine for the&#xD;
      prevention of Pneumocystis carinii pneumonia is allowed, but other investigational drugs are&#xD;
      not. Drug effects on the HIV virus, immune function, and clinical condition will be monitored&#xD;
      during the periodic evaluations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">April 1990</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>60</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextran sulfate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Aerosolized pentamidine for prophylaxis of Pneumocystis carinii pneumonia (PCP).&#xD;
&#xD;
          -  Acetaminophen.&#xD;
&#xD;
          -  Ketoconazole.&#xD;
&#xD;
        Consistently positive serum HIV p24 antigen = or &gt; 70 picograms/ml, defined by the Abbott&#xD;
        HIV antigen test, on two occasions, each within 1 month prior to entry, separated by at&#xD;
        least 72 hours, the last of which must be within 2 weeks of starting therapy. Positive&#xD;
        antibody to HIV with a federally licensed ELISA test kit.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Patients with any negative HIV p24 antigen test within 1 month of entry are excluded.&#xD;
        Hemophiliacs are excluded.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded within 4 weeks of study entry:&#xD;
&#xD;
          -  Biologic response modifiers.&#xD;
&#xD;
          -  Zidovudine (AZT) or other antiretroviral agents.&#xD;
&#xD;
          -  Other investigational drugs.&#xD;
&#xD;
          -  Excluded within 12 weeks of study entry:&#xD;
&#xD;
          -  Ribavirin.&#xD;
&#xD;
          -  Excluded:&#xD;
&#xD;
          -  Ongoing therapy and/or prophylaxis for an AIDS-defining opportunistic infection.&#xD;
&#xD;
          -  Anticoagulant drugs.&#xD;
&#xD;
          -  Systemic corticosteroids.&#xD;
&#xD;
          -  Aspirin.&#xD;
&#xD;
          -  Dextran sulfate.&#xD;
&#xD;
          -  Sedatives.&#xD;
&#xD;
          -  Barbiturates.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded within 2 weeks of study entry:&#xD;
&#xD;
          -  Transfusion.&#xD;
&#xD;
        Severe diarrhea:&#xD;
&#xD;
          -  = or &gt; 5 loose or watery stools per day. Significant malabsorption:&#xD;
&#xD;
          -  &gt; 10 percent weight loss within past 3 months with serum carotene &lt; 75 IU/ml or&#xD;
             vitamin A &lt; 75 IU/ml. Transfusion dependent:&#xD;
&#xD;
          -  Requiring 2 units of blood &gt; once a month. Active opportunistic infection. Symptomatic&#xD;
             visceral Kaposi's sarcoma (KS), progression of KS within 1 month of entry, or&#xD;
             concurrent neoplasms other than KS. Basal cell carcinoma of the skin or in situ&#xD;
             carcinoma of the cervix. Hemorrhagic diseases such as hemophilia A or B or von&#xD;
             Willebrand disease.&#xD;
&#xD;
        Active drug or alcohol abuse sufficient in the investigator's opinion to prevent adequate&#xD;
        compliance with study therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abrams D</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Los Angeles County - USC Med Ctr</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA CARE Ctr</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Francisco AIDS Clinic / San Francisco Gen Hosp</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>941102859</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>George Washington Univ Med Ctr</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Massachusetts Med Ctr</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mem Sloan - Kettering Cancer Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Luke's - Roosevelt Hosp Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Falloon J, et al. 566C80 for the treatment of Pneumocystis carinii pneumonia in AIDS. Int Conf AIDS. 1991 Jun 16-21;7(2):241 (abstract no WB2239)</citation>
  </reference>
  <reference>
    <citation>Abrams D, Pettinelli C, Power M, Kubacki VB, Grieco MH, Henry WK. A phase I/II dose ranging trial of oral dextran sulfate in HIV p24 antigen positive individuals (ACTG 060): results of a safety and efficacy trial. Int Conf AIDS. 1989 Jun 4-9;5:404 (abstract no WBP315)</citation>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>T-Lymphocytes</keyword>
  <keyword>HIV Antigens</keyword>
  <keyword>Dextran Sulfate</keyword>
  <keyword>Dose-Response Relationship, Drug</keyword>
  <keyword>Drug Evaluation</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>AIDS-Related Complex</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dextrans</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

